Ovarian serous borderline tumors (SBTs) are presumed to originate in the ovarian cortex or peritoneal surface. The pathogenetic role of the fallopian tube (FT) is unclear; however, recently, secretory cell outgrowths (SCOUTs) lacking PAX2 expression were described in benign FTs. This study addressed (1) the differentiation characteristics of SBTs and (2) the frequency of SCOUTs lacking PAX2 expression in the FTs of patients with SBTs and compared (3) SCOUT morphology and (4) PAX2 expression with SBTs. SBTs and FT epithelium shared both ciliated (p73) and secretory (HMFG2) differentiation. PAX2-null SCOUT frequency in FT cross-sections from patients with SBTs was 0.28 (110 of 398) versus 0.112 in benign hysterectomies and nearly 0 in pediatric and postpartum sterilization specimens (P =<0.001). When adjusted for age, the differences narrowed but remained significant (P = 0.010). SCOUTs were heterogeneous, some displaying ciliated differentiation and papillary architecture. Two cases of discrete multifocal papillary SCOUTs in the FTs were associated with SBTs. All SBTs had heterogeneous PAX2 staining with areas of PAX2 loss. This study shows for the first time that PAX2-null SCOUTs are more common in the oviducts of women with SBTs and that loss of PAX2 expression occurs in most SBTs. These discoveries link both morphologic and functional gene (PAX2) alterations in the oviduct to SBTs, similar to that reported in high-grade serous carcinoma. Further study is warranted to clarify the relationship of the oviduct to serous neoplasia.
S erous borderline tumors (SBTs) of the ovary are predominantly clonal neoplasms, and they fall between benign serous cystadenoma and high-grade serous carcinoma in the spectrum of ovarian serous tumors. 21 Serous tumors have traditionally been thought to arise from the ovarian surface epithelium or from the Mu¨llerian epithelium within the ovary. 8, 21 Recently, the fallopian tube was implicated as a primary site for some high-grade serous carcinomas, and a spectrum of changes ranging from frank serous tubal intraepithelial carcinoma to a precursor condition (p53 signature) has been described, all linked by mutations in the tumor suppressor gene p53. 2, 7, 9, 15 More recently, the spectrum of potential precursors in the fallopian tube was expanded to include more generic secretory cell outgrowths (SCOUTs), which are characterized by loss of PAX2 expression (PAX2 null). The latter have been linked to high-grade serous carcinoma, both by their greater association with this malignancy relative to controls and by the loss of PAX2 expression. 2 Epithelial hyperplasia has also been noted in the fallopian tubes of patients with SBTs, but its significance is unknown. 16 We previously identified 2 cases with unique multifocal proliferations (SCOUTs) in benign fallopian tubes from 2 women with serous cystadenomas with borderline features. The purpose of this study was to describe these 2 cases and to examine the relationship between SCOUTs and SBTs. Thus, we explored fallopian tubes with the intent to determine the frequency of PAX2null SCOUTs in the fallopian tubes of patients with SBTs as compared with controls, examine SCOUT morphology in more detail, describe the differentiation characteristics of SBTs, and compare PAX2 expression patterns in SCOUTs and SBTs.
MATERIALS AND METHODS

Study Material
This study was approved by the Institutional Review Board at Brigham & Women's Hospital and Children's Hospital. Consecutive SBTs obtained between 2007 and 2010 comprised the cases (n = 48), with fallopian tubes available for review in 33 of these cases. Additional SBTs (n = 14) from archival material were evaluated for selected immunohistochemical studies. Controls consisted of 3 populations: fallopian tubes from pediatric autopsies (n = 20), postpartum sterilizations (n = 25), and salpingo-oophorectomies associated with benign hysterectomies from women without ovarian pathology (eg, leiomyomata, n = 20). Age-specific data were obtained from adults, but data on age were not available from the pediatric group. Two unique cases of proliferations in the fallopian tubes associated with SBT were studied separately.
Immunohistochemistry
The following antibodies were used, with methods as previously described.
p73 (Antibody courtesy of Frank McKeon): p73 is a gene with homology to p53, but without a clear tumor suppressor function, which is expressed in the nuclei of ciliated cells of the respiratory tract and fallopian tube and in several foci within the central nervous system. 25 Cases were scored as positive by the presence of nuclear staining, which contrasts with stromal and secretory cells. 9
HMFG2
HMFG2 is a monoclonal antibody that binds to a particular glycoform of the high-molecular-weight transmembrane glycoprotein MUC1. MUC1 is expressed on the apical aspect of simple epithelial cells, including those of the female genital tract and more specifically of the fallopian tube, 19 in which it is a marker for secretory cells. 4 A positive reaction was cytoplasmic staining that was absent in the subjacent stromal and ciliated cells. 9
PAX2
PAX2 is a member of the paired box transcription factor gene family that is critical in the embryogenesis and organogenesis of the central nervous system, eye, ear, and the genitourinary tract. PAX2 is expressed throughout the female genital tract, including in the endometrial epithelium, and in particular in the secretory cells of the fallopian tube epithelium. (Invitrogen, Cat# 71-6000). 2, 23 Nuclear immunolocalization parallels that of PAX8.
Fourteen archival SBTs were stained for evidence of ciliated (p73) and secretory (HMFG2) differentiation ( Fig. 1 ). Fallopian tubes and ovarian tumors from 33 patients with SBTs were stained with PAX2, the former to ascertain the frequency of PAX2-null SCOUTs and the latter to determine the distribution of PAX2 in the tumors. PAX2-null SCOUTs were defined as at least 30 consecutive horizontally arranged cells that contained predominantly secretory cells and were devoid of nuclear PAX2 staining (Fig. 2 ). The number of SCOUTs and number of FT cross-sections were recorded and expressed as a ratio (frequency) of PAX2-null SCOUTs per section. The differentiation characteristics (secretory cells only vs. secretory with ciliated cells) of each SCOUT were also recorded.
Data Analysis
The data were analyzed to compare: (1) histopathology and immunophenotype of PAX2-null SCOUTs with normal salpingeal mucosa and SBTs and (2) the frequencies of PAX2-null SCOUTs per tubal crosssection in cases (SBTs) and controls (pediatric autopsies, postpartum sterilizations, and hysterectomies for benign ovarian disorders). Differences in the aggregate data (PAX2-null SCOUTs per cross-section in each group) were analyzed by w 2 analysis. To account for age differences and the varying numbers of sections examined for each subject, the data were modeled on the assumption that the number of SCOUTS in each section follows a Poisson distribution, with Poisson rate depending on group and age and the number of sections examined. The data were adjusted for age in the model, using 10-year groupings (25 to 35, 35 to 45, etc). The Poisson probability distribution is commonly used to model count data; it is a 1-parameter distribution ,and it fixes the variance to be equal to the mean. As this is often overly restrictive, it may be extended by assuming variability of the Poisson parameter across subjects, which yields a negative binomial model.
RESULTS
Immunostaining of SBTs for Evidence of Ciliated and Secretory Differentiation
Fourteen cases of SBT were immunostained for both secretory (HMFG2) and ciliated (p73) differentiation. In all, there was evidence of both immunophenotypes ( Fig. 1 ). However, despite the immunophenotypic parallels between borderline serous tumors and normal salpingeal epithelium, there was a wider range of cellular morphology in the borderline tumors. Nuclear p73 immunostaining could be appreciated both in conspicuous ciliated cells and in cells with apical eosinophilia suggestive of terminal bar preservation. The latter were interpreted as evidence of the ciliated phenotype and were more typical of borderline tumors in contrast to normal salpingeal epithelium. Cortical inclusion cysts were also immunostained and exhibited a similar immunophenotype (not shown).
Fallopian Tubes With Marked Epithelial Proliferation Associated With SBT of the Ovary
The histologic findings in these 2 cases were very similar. In each case, multiple discrete papillary structures were evident on low power, distributed throughout the cross-sections of fallopian tubes and evenly distributed throughout the oviduct (Figs. 3A, B) . These structures had a focally complex branching architecture and were lined by an epithelium that appeared lush in comparison with the background tubal epithelium (Figs. 3C-F). The epithelium was pseudostratified, focally tufted, and comprised both secretory and ciliated cells. Differentiation and Immunophenotype of PAX2-Null SCOUTs PAX2-null SCOUT morphology varied, and 3 different patterns were identified. The first consisted of almost exclusively secretory-type cells with elongated nuclei arranged in a single or mildly pseudostratified layer ( Fig. 2A) . The second consisted of a multilayered epithelium with scattered inflammatory cells (Fig. 2B) . The appearance suggested a mixed secretory and ciliated phenotype; however, conspicuous cilia were not present. The third, which was the least commonly encountered, contained a conspicuous ciliated component, often with some papillary architecture and scattered inflammatory cells (Fig. 2C ). All 3 types showed a loss of nuclear PAX2 staining (Figs. 2D-F). 
PAX2-Null SCOUT Frequency in the Fallopian Tubes of Patients With SBTs Relative to Controls
For each case a frequency distribution of SCOUTs expressed as a fraction of the total number of tubal crosssections examined was compiled. The distribution of individual frequencies for cases and controls is summarized in Table 1 . Overall, the average frequency of SCOUTs per cross-section in 33 SBTs was 0.276 (110 of 398). This was in contrast to essentially zero SCOUTs per cross-section examined in both 20 pediatric autopsies (0 of 35) and 25 postpartum sterilizations (1 of 190) and 0.112 in 20 benign salpingo-oophorectomies (18 of 161) ( Fig. 4 and Table 1 ). On comparing the aggregate data for each group, these differences were highly significant (P =<0.001) by w 2 analysis. When adjusted for age group (in 10-y intervals) and number of sections (from the negative binomial regression model) the difference in frequency of SCOUTs between SBT and control-associated fallopian tubes remained significant (P = 0.010).
PAX2 Immunostaining in SBTs
As SCOUTs have a high frequency of loss of PAX2 staining, we analyzed 33 SBTs to determine the range of immunostaining in these tumors. All of the SBTs were heterogeneous for PAX2 ( Fig. 5 ). Thirty-five percent showed >80% positivity, 56% were 20% to 80% positive, and in 9%, <20% of the cells stained for PAX2. This was compared with a recent study by Roh et al 17 of high-grade Mu¨llerian carcinomas of the pelvis. In that study 72% of cases were PAX2 null in >90% of tumor cells; the remaining 28% were either PAX2 positive or heterogeneous for PAX2 staining.
DISCUSSION
There is remarkable similarity between serous ovarian tumors and salpingeal epithelium, both in morphology and gene expression. 11, 16 An intriguing finding is the coexistence of both ciliated and secretory cells in SBTs, similar to the normal oviduct. One difference is the apparent broader range of p73 immunostaining, which can be seen in cells without conspicuous cilia, a feature more commonly encountered in SBTs. This mixed phenotype is also characteristic of Mu¨llerian inclusions in the ovarian cortex, which were also present in the cases immunostained and which presumably give rise to SBTs. 5, 12, 14, 21 Whether this benign ovarian "precursor" condition is derived from the fallopian tube or through mesothelial-to-Mu¨llerian transdifferentiation of the ovarian surface lining is controversial. 1 However, irrespective of the mechanism, ovarian cortical inclusions are a de facto representation of the salpingeal phenotype in the ovarian cortex. Another intriguing aspect of this mixed epithelial differentiation seen in SBTs is the suggestion based on a recent study that SBTs emanate from a single clone of transformed progenitor cells. 22 This possibility takes on added significance with the identification of SCOUTs in the fallopian tube-a common occurrence (Fig. 2) -and, more rarely, of more conspicuous micropapillary proliferations ( Fig. 3) with both a secretory and ciliated cell phenotype. Together, these observations present compelling evidence for the capacity of the oviductal epithelium for both expansion and, at the same time, bidirectional (secretory and ciliated) differentiation.
This study cannot determine with certainty whether SBTs are directly derived from SCOUTs. Nevertheless, there appears to be a relationship between these discrete changes in the oviduct and SBTs. We have previously shown that SCOUTs exist in the fallopian tube, occur throughout the entire length of the organ, are increased in frequency in cases of high-grade serous cancer, and frequently are PAX2 null. 2 The current analysis was intended to explore the possibility that PAX2-null SCOUTs were more frequent in SBTs. As shown in Figure 2 and Table 1 , there is a range of PAX2-null SCOUTs in these tubes, and as a group they are highly significantly associated with the presence of SBT. The relationship of PAX2 staining to both SCOUTs and their associated SBTs is less clear, but there is evidence of loss of PAX2 expression in the latter (Fig. 5) . The contrast between complete loss of PAX2 expression in SCOUTs and the heterogeneous staining in SBTs might seem paradoxical. However, similar contrasts in staining frequency can be seen between SCOUTs (including p53 signatures) and high-grade serous carcinomas. 2, 17 One explanation is that the emergence of SCOUTs is associated with a consistent downregulation of certain genes (PAX2 and others), whereas the onset of malignancy, accompanied by a presumably broader range of gene dysregulations, may reverse this process in portions of the tumor. 17 The observation of both secretory and ciliated cell differentiation in putative clonal (SBTs) neoplasms may have a parallel in PAX2-null SCOUTs. 22 The latter are yet to be established as clonal; however, they could be explained by alteration of a cell with capacity to differentiate into both cell types, similar to SBTs. In this study, an effort was made to standardize the tabulation of SCOUT frequency as much as possible by computing it as a function of the number of cross-sections examined. This revealed significant differences in frequency between controls and SBTs. However, the controls varied considerably in terms of frequency of PAX2-null SCOUTs. SCOUTs were virtually absent from the fallopian tubes of pediatric autopsies and postpartum sterilization specimens. It is important to emphasize that both increasing age and number of sections examined appear to influence the number of SCOUTs detected. Thus, SCOUTs may not signify as much a precursor as a reflection of a more global dysregulation of genes in oviductal secretory epithelium that occurs with increasing age. This phenomenon may have significance beyond its association with SBTs and bears further analysis in the context of multiple variables and other epithelial neoplasms in the reproductive tract.
The distribution of SBTs is not unlike that of highgrade serous carcinomas, given the involvement of ovaries and peritoneal surfaces. On the basis of the findings in this study, it is conceivable that a precursor condition originating in the FT in a field of multifocal gene dysregulation might gain a growth advantage over pelvic/ovarian surface mesothelium, leading to SBT. Alternatively, the factors influencing the development of PAX2-null SCOUTs in the tube could also be at play in the ovarian cortex within stromal-epithelial interactions. Confirmation of either model could be germane to the origins of both low-grade and high-grade pelvic serous neoplasms.
The more pronounced multifocal micropapillary lesions seen in 2 individuals and illustrated in Figure 3 are similar to SCOUTs, albeit more striking in their level of architectural development, and raise the intriguing possibility that the affected individuals have a unique susceptibility to epithelial outgrowths in the oviduct. Parallels can be seen to germline BRCA1 or BRCA2 mutations, reportedly associated with a significantly higher index of proliferation (and malignancy), 3, 13, 15 to fallopian tubes from women with Li Fraumeni syndrome, which have multiple p53 signatures, 24 and to other germline mutation-related syndromes with multifocal neoplasia. 6, 10, 20 The described tubal proliferations, including SCOUTs, bear some resemblance to microadenomas described in colonic carcinogenesis. 18 Whether they have a similar significance remains to be determined, but their study may uncover novel pathways that intersect with those involved in the genesis of serous neoplasia.
